Plus Therapeutics, Inc.
PSTV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,824 | $4,913 | $224 | $0 |
| % Growth | 18.5% | 2,093.3% | – | – |
| Cost of Goods Sold | $852 | $9,690 | $712 | $66 |
| Gross Profit | $4,972 | -$4,777 | -$488 | -$66 |
| % Margin | 85.4% | -97.2% | -217.9% | – |
| R&D Expenses | $10,580 | $9,690 | $9,698 | $5,323 |
| G&A Expenses | $9,939 | $8,544 | $0 | $6,853 |
| SG&A Expenses | $9,939 | $8,544 | $9,526 | $6,853 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$852 | -$9,690 | $0 | $250 |
| Operating Expenses | $19,667 | $8,544 | $19,224 | $12,426 |
| Operating Income | -$14,695 | -$13,321 | -$19,712 | -$12,492 |
| % Margin | -252.3% | -271.1% | -8,800% | – |
| Other Income/Exp. Net | $1,717 | $5 | -$563 | -$907 |
| Pre-Tax Income | -$12,978 | -$13,316 | -$20,275 | -$13,399 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,978 | -$13,316 | -$20,275 | -$13,399 |
| % Margin | -222.8% | -271% | -9,051.3% | – |
| EPS | -1.95 | -4.24 | -11.55 | -17.78 |
| % Growth | 54% | 63.3% | 35% | – |
| EPS Diluted | -2.34 | -4.24 | -11.55 | -17.78 |
| Weighted Avg Shares Out | 6,640 | 3,141 | 1,750 | 805 |
| Weighted Avg Shares Out Dil | 7,701 | 3,141 | 1,750 | 806 |
| Supplemental Information | – | – | – | – |
| Interest Income | $273 | $400 | $147 | $19 |
| Interest Expense | $3,724 | $395 | $711 | $932 |
| Depreciation & Amortization | $852 | $628 | $712 | $419 |
| EBITDA | -$8,402 | -$12,693 | -$18,852 | -$12,048 |
| % Margin | -144.3% | -258.4% | -8,416.1% | – |